|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for CDKL2 |
 Gene summary |
| Basic gene Info. | Gene symbol | CDKL2 |
| Gene name | cyclin-dependent kinase-like 2 (CDC2-related kinase) | |
| Synonyms | KKIAMRE|P56 | |
| Cytomap | UCSC genome browser: 4q21.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_003948.3, | |
| Description | CDC2-related kinasecyclin-dependent kinase-like 2p56 KKIAMRE protein kinaseprotein kinase p56 KKIAMREserine/threonine protein kinase KKIAMREserine/threonine-protein kinase KKIAMRE | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 603442 | |
| HGNC : HGNC | ||
| HPRD : 16021 | ||
| Protein | UniProt: Q92772 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CDKL2 | |
| BioGPS: 8999 | ||
| Pathway | NCI Pathway Interaction Database: CDKL2 | |
| KEGG: CDKL2 | ||
| REACTOME: CDKL2 | ||
| Pathway Commons: CDKL2 | ||
| Context | iHOP: CDKL2 | |
| ligand binding site mutation search in PubMed: CDKL2 | ||
| UCL Cancer Institute: CDKL2 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for CDKL2 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | A148 | R149L | COAD | 2 | A148 | R149Q | COAD | 2 | Y15,G11 | G13R | COAD | 1 | A148 | R149G | COAD | 1 | Y15 | S14G | STAD | 1 | E130 | E130D | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for CDKL2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | A148 | R149L | 0.35580845 | Y15 | S14G | -1.2343691 | E130 | E130D | -0.88375055 | A148 | R149G | -0.60170752 | Y15 | G13R | -0.27389585 | G11 | G13R | -0.27389585 | A148 | R149Q | -0.27116839 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for CDKL2 from PDB |
| PDB ID | PDB title | PDB structure | 4AAA | CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN |  |
| Top |
| Differential gene expression and gene-gene network for CDKL2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for CDKL2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for CDKL2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of CDKL2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | DKI | CDK1/2 INHIBITOR III | 4aaa | A | G11 Y15 E130 | TC0 | 4'-[5-[[3-[(CYCLOPROPYLAMINO)METHYL]PHENYL] AMINO]-1H-PYRAZOL-3-YL]-[1,1'-BIPHENYL]-2,4- DIOL | 4bbm | A | Y15 | TC0 | 4'-[5-[[3-[(CYCLOPROPYLAMINO)METHYL]PHENYL] AMINO]-1H-PYRAZOL-3-YL]-[1,1'-BIPHENYL]-2,4- DIOL | 4bbm | B | Y15 A148 |
| Top |
| Conservation information for LBS of CDKL2 |
| Multiple alignments for Q92772 in multiple species |
| LBS | AA sequence | # species | Species | A148 | CDFGFARTLAA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | A31 | SGRIVAIKKFL | 2 | Mus musculus, Rattus norvegicus | A31 | TGRIVAIKKFL | 1 | Homo sapiens | C143 | GVVKLCDFGFA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D144 | VVKLCDFGFAR | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D84 | VFEFVDHTILD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D89 | DHTILDDLKLF | 2 | Mus musculus, Rattus norvegicus | D89 | DHTILDDLELF | 1 | Homo sapiens | E130 | RDIKPENILVS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E81 | WYLVFEFVDHT | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F147 | LCDFGFARTLA | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F80 | RWYLVFEFVDH | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F82 | YLVFEFVDHTI | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G11 | NLGLVGEGSYG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | H85 | FEFVDHTILDD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L133 | KPENILVSQSG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | T86 | EFVDHTILDDL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V10 | ENLGLVGEGSY | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V18 | GSYGMVMKCRN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V64 | RHENLVNLLEV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V83 | LVFEFVDHTIL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | Y15 | VGEGSYGMVMK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |